Aileron Therapeutics Inc (NASDAQ:ALRN) Director Rickenbach Josef H. Von bought 113,145 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $0.98 per share, for a total transaction of $110,882.10.
ALRN traded up $0.03 during mid-day trading on Tuesday, hitting $1.01. 300 shares of the stock were exchanged, compared to its average volume of 391,945. The firm’s fifty day moving average is $0.68 and its two-hundred day moving average is $1.13. Aileron Therapeutics Inc has a 1-year low of $0.44 and a 1-year high of $3.54. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.16. The company has a market cap of $27.84 million, a PE ratio of -0.49 and a beta of 2.27.
Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). As a group, research analysts anticipate that Aileron Therapeutics Inc will post -1.14 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC lifted its stake in Aileron Therapeutics by 649.6% during the 1st quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock worth $3,828,000 after acquiring an additional 1,768,073 shares in the last quarter. Deutsche Bank AG raised its position in Aileron Therapeutics by 432.9% in the 4th quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after purchasing an additional 104,932 shares in the last quarter. Vanguard Group Inc. raised its position in Aileron Therapeutics by 261.6% in the 2nd quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after purchasing an additional 240,910 shares in the last quarter. Finally, BlackRock Inc. raised its position in Aileron Therapeutics by 179.6% in the 2nd quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after purchasing an additional 31,787 shares in the last quarter. 26.00% of the stock is currently owned by hedge funds and other institutional investors.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Read More: Bollinger Bands
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.